Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Functional genomics to uncover drug mechanism of action
Sebastian Nijman
Nature Chemical Biology (2015) Vol. 11, Iss. 12, pp. 942-948
Closed Access | Times Cited: 75

Showing 1-25 of 75 citing articles:

Opportunities and challenges in phenotypic drug discovery: an industry perspective
John G. Moffat, Fabien Vincent, Jonathan A. Lee, et al.
Nature Reviews Drug Discovery (2017) Vol. 16, Iss. 8, pp. 531-543
Open Access | Times Cited: 823
Advances in targeting ‘undruggable’ transcription factors with small molecules
Matthew J. Henley, Angela N. Koehler
Nature Reviews Drug Discovery (2021) Vol. 20, Iss. 9, pp. 669-688
Closed Access | Times Cited: 264
Systematic Immunotherapy Target Discovery Using Genome-Scale In Vivo CRISPR Screens in CD8 T Cells
Matthew B. Dong, Guangchuan Wang, Ryan D. Chow, et al.
Cell (2019) Vol. 178, Iss. 5, pp. 1189-1204.e23
Open Access | Times Cited: 254
High-Throughput Screening: today’s biochemical and cell-based approaches
Vincent Blay, Bhairavi Tolani, Sunita P. Ho, et al.
Drug Discovery Today (2020) Vol. 25, Iss. 10, pp. 1807-1821
Closed Access | Times Cited: 233
Combined CRISPRi/a-Based Chemical Genetic Screens Reveal that Rigosertib Is a Microtubule-Destabilizing Agent
Marco Jost, Yuwen Chen, Luke A. Gilbert, et al.
Molecular Cell (2017) Vol. 68, Iss. 1, pp. 210-223.e6
Open Access | Times Cited: 231
Applications of chemogenomic library screening in drug discovery
Lyn H. Jones, Mark E. Bunnage
Nature Reviews Drug Discovery (2017) Vol. 16, Iss. 4, pp. 285-296
Closed Access | Times Cited: 179
Machine learning and image-based profiling in drug discovery
Christian Scheeder, Florian Heigwer, Michael Boutros
Current Opinion in Systems Biology (2018) Vol. 10, pp. 43-52
Open Access | Times Cited: 156
Prediction of Synergism from Chemical-Genetic Interactions by Machine Learning
Jan Wildenhain, Michaela Spitzer, Sonam Dolma, et al.
Cell Systems (2015) Vol. 1, Iss. 6, pp. 383-395
Open Access | Times Cited: 112
Genotoxicity testing: progress and prospects for the next decade
Hasan Türkez, Mehmet Enes Arslan, Özlem Özdemir Tozlu
Expert Opinion on Drug Metabolism & Toxicology (2017) Vol. 13, Iss. 10, pp. 1089-1098
Closed Access | Times Cited: 108
Target identification of small molecules using large-scale CRISPR-Cas mutagenesis scanning of essential genes
Jasper E. Neggers, Bert Kwanten, Tim Dierckx, et al.
Nature Communications (2018) Vol. 9, Iss. 1
Open Access | Times Cited: 102
Use of artificial intelligence to enhance phenotypic drug discovery
Sophia Malandraki-Miller, Paul R. Riley
Drug Discovery Today (2021) Vol. 26, Iss. 4, pp. 887-901
Closed Access | Times Cited: 59
Recent advances of targeting nicotinamide phosphoribosyltransferase (NAMPT) for cancer drug discovery
He Tang, Lin Wang, Tianyu Wang, et al.
European Journal of Medicinal Chemistry (2023) Vol. 258, pp. 115607-115607
Closed Access | Times Cited: 23
Functional CRISPR screens in T cells reveal new opportunities for cancer immunotherapies
Minghua Xiang, Huayi Li, Yuanyuan Zhan, et al.
Molecular Cancer (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 9
CRISPR Approaches to Small Molecule Target Identification
Marco Jost, Jonathan S. Weissman
ACS Chemical Biology (2017) Vol. 13, Iss. 2, pp. 366-375
Open Access | Times Cited: 77
Turning liabilities into opportunities: Off-target based drug repurposing in cancer
Vinayak Palve, Yi Liao, Lily Rix, et al.
Seminars in Cancer Biology (2020) Vol. 68, pp. 209-229
Open Access | Times Cited: 68
Mass spectrometry-based Cellular Thermal Shift Assay (CETSA®) for target deconvolution in phenotypic drug discovery
Tomas Friman
Bioorganic & Medicinal Chemistry (2019) Vol. 28, Iss. 1, pp. 115174-115174
Closed Access | Times Cited: 55
Computational analyses of mechanism of action (MoA): data, methods and integration
Maria‐Anna Trapotsi, Layla Hosseini-Gerami, Andreas Bender
RSC Chemical Biology (2021) Vol. 3, Iss. 2, pp. 170-200
Open Access | Times Cited: 49
The anticancer natural product ophiobolin A induces cytotoxicity by covalent modification of phosphatidylethanolamine
Christopher Chidley, Sunia A. Trauger, Kıvanç Birsoy, et al.
eLife (2016) Vol. 5
Open Access | Times Cited: 56
Application of Omics Technologies for Evaluation of Antibacterial Mechanisms of Action of Plant-Derived Products
Bruno Souza dos Santos, Luís Cláudio Nascimento da Silva, Túlio D. da Silva, et al.
Frontiers in Microbiology (2016) Vol. 7
Open Access | Times Cited: 55
Gain- and Loss-of-Function Mutations in the Breast Cancer Gene GATA3 Result in Differential Drug Sensitivity
Barbara Mair, Tomasz Konopka, Claudia Kerzendorfer, et al.
PLoS Genetics (2016) Vol. 12, Iss. 9, pp. e1006279-e1006279
Open Access | Times Cited: 54
The development of high-content screening (HCS) technology and its importance to drug discovery
Ivan Fraietta, Fabio Gasparri
Expert Opinion on Drug Discovery (2016) Vol. 11, Iss. 5, pp. 501-514
Closed Access | Times Cited: 51
Bioactive Compound Collections: From Design to Target Identification
Luca Laraia, Lucas Robke, Herbert Waldmann
Chem (2018) Vol. 4, Iss. 4, pp. 705-730
Open Access | Times Cited: 51
CRISPR/CAS9-based DNA damage response screens reveal gene-drug interactions
Dan Su, Xu Feng, Medina Colic, et al.
DNA repair (2020) Vol. 87, pp. 102803-102803
Open Access | Times Cited: 41
High‐content drug screening for rare diseases
Francesco Bellomo, Diego L. Medina, Ester De Leo, et al.
Journal of Inherited Metabolic Disease (2017) Vol. 40, Iss. 4, pp. 601-607
Closed Access | Times Cited: 37
Identifying antimalarial compounds targeting dihydrofolate reductase-thymidylate synthase (DHFR-TS) by chemogenomic profiling
Aiyada Aroonsri, Olugbenga Akinola, Navaporn Posayapisit, et al.
International Journal for Parasitology (2016) Vol. 46, Iss. 8, pp. 527-535
Closed Access | Times Cited: 36
Page 1 - Next Page

Scroll to top